Dear members, please see the latest MedTech Europe update on the weekly ECHA news. If you impacted by any of these reviews, then please let me know at regulatory@bivda.org.uk
With this email, we would like to inform you about the latest chemical developments at ECHA and kindly ask you to indicate if any of the following impact your company by 25 February.
Please note that the substances highlighted in yellow are the ones already identified as potentially in use in our sector.
CLP
- Consultations on harmonised classification and labelling. Feedback period between 16 February 2026 and 17 April 2026 – link here:
- N-ethyl-N-[2-[1-(2-methylpropoxy)ethoxy]ethyl]-4-(phenylazo)aniline (EC 252-021-1, CAS 34432-92-3)
- 1,3,5-triazine-2,4,6-triamine; melamine (EC 203-615-4, CAS 108-78-1)
- Proposals to harmonise classification and labelling – link here:
- Vanadate(1-), oxo[phosphato(3-)-κO]-, hydrogen, hydrate (2:2:1) (EC -, CAS 93280-40-1)
- Ammonium trioxovanadate (EC 232-261-3, CAS 7803-55-6)
- Sodium metavanadate (EC 237-272-7, CAS 13718-26-8)
- Potassium vanadium trioxide (EC 237-388-8, CAS 13769-43-2)
In addition, ECHA published the assessment of regulatory needs reports for the following groups:
